Treatment Efficacy

Overview

The coronavirus is a family of viruses that can cause respiratory diseases in humans, ranging from the common cold to severe respiratory infections such as severe acute respiratory syndrome (SARS) and the recently emerged coronavirus disease (COVID-19). COVID-19 emerged in Wuhan, China, in December 2019 and has since spread globally, resulting in a pandemic. The urgent need to find effective treatments for this pandemic necessitates the publication of high-quality research in the International Journal of Coronavirus. When it comes to treating COVID-19, there is currently no FDA-approved antiviral medication or vaccine available. However, there are promising treatments that have been tested both in clinical settings and in vitro. Some of these treatments include Remdesivir, Chloroquine, Hydroxychloroquine, and combination therapy with lopinavir/ritonavir, interferons, and other drugs. Novel therapies such as monoclonal antibodies and convalescent plasma are also being studied. The efficacy of these treatments is still being studied and debated by the scientific community. Many observational studies have suggested that these treatments may have positive effects on COVID-19 patients, while others have yielded conflicting results. There is a dire need for more randomized clinical trials to evaluate the safety and efficacy of these treatments. In conclusion, effective treatments for COVID-19 are currently lacking, but many different approaches are being investigated. The International Journal of Coronavirus will serve as a valuable platform for publishing high-quality research on promising COVID-19 treatment options, ultimately contributing to the development of novel and effective treatments for the battle against the COVID-19 pandemic.

Research published in this journal

11 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 11 articles above have been cited 15 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

• What guides back pain care? A content analysis of low back pain directives in the Australian context
  2023 · Health Research Policy and Systems
• What guides back pain care? A content analysis of low back pain directives in the Australian context
  2023 · Health Research Policy and Systems
• Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
  Jaekwon Seok et al. · 2023 · Journal of Translational Medicine
• CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons
  2022 · JCI Insight
• What guides back pain care? A content analysis of low back pain directives in the Australian context
  2022 · Research Square (Research Square)
• J591 functionalized paclitaxel loaded PLGA nanoparticles successfully inhibited PSMA overexpressing LNCaP cells
  Iman Ehsan et al. · 2022 · Journal of Drug Delivery Science and Technology
• CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons
  2022 · JCI Insight
• Adherence to Antiretroviral Therapy (Art) among Pregnant Women Living with HIV/AIDS in Okigwe Imo State, Nigeria
  E. C. Uloeme et al. · 2022 · Asian Journal of Biochemistry Genetics and Molecular Biology

A sample of recent works citing this journal's research on Treatment Efficacy, linking to each citing work.

This page summarises published research for orientation; it is not medical or professional advice.

Related topics